Gastrointestinal Cancer

Top Story

Sorafenib benefit dependent on hepatitis status in patients with HCC

February 19, 2017

Sorafenib improved OS among patients with hepatocellular carcinoma who were hepatitis C positive but hepatitis B negative, suggesting that the beneficial effects of sorafenib may be based on hepatitis status, according to results of a meta-analysis.

“Irrespective of the mechanism, our data suggest that in future trials in HCC, particularly where sorafenib is the control arm, there should be stratification according to etiology,” Richard Jackson, BSc, MSc, from the Liverpool Cancer Trials Unit of University of Liverpool in United Kingdom, and colleagues wrote. “Etiological differences have already been considered as factors in the interpretation of clinical trials.”

Tivantinib fails to improve OS in hepatocellular carcinoma

February 17, 2017
A phase 3 study of tivantinib as second-line treatment for hepatocellular carcinoma failed to meet its primary endpoint of improved OS, according to the drug’s…
In the Journals

Long-term weight gain linked to esophageal, gastric cancers

February 16, 2017
Individuals who become overweight in their twenties and progress to obesity later in life may have a threefold increased risk for developing esophageal and gastric…

NYU Langone names liver tumor program director

February 14, 2017
Theodore H. Welling, III, MD, has been named director of a new liver tumor program at NYU Langone’s Perlmutter Cancer Center. Welling’s team will focus on…
CME

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease…
More »
Video

VIDEO: Toxicities related to immune therapies ‘unpredictable’ but ‘manageable’

June 23, 2016
More »
In the Journals Plus

Sorafenib benefit dependent on hepatitis status in patients with HCC

February 19, 2017
Sorafenib improved OS among patients with hepatocellular carcinoma who were hepatitis C positive but hepatitis B negative, suggesting that the…

Tivantinib fails to improve OS in hepatocellular carcinoma

February 17, 2017
A phase 3 study of tivantinib as second-line treatment for hepatocellular carcinoma failed to meet its primary endpoint of improved OS, according to…

In the Journals

Long-term weight gain linked to esophageal, gastric cancers

February 16, 2017
Individuals who become overweight in their twenties and progress to obesity later in life may have a threefold increased risk for developing…

NYU Langone names liver tumor program director

February 14, 2017
Theodore H. Welling, III, MD, has been named director of a new liver tumor program at NYU Langone’s Perlmutter Cancer Center. Welling’s…

FDA: More adolescents with cancer should be included in adult trials

February 13, 2017
Enrollment of adolescents in oncology trials remains significantly lower than that of children. Consequently, the FDA has urged the research…

In the Journals Plus

Use of metaphors may improve participation in clinical trials

February 11, 2017
The use of metaphors for explaining randomization could ease the difficulty in recruiting patients to participate in randomized clinical trials…

‘Explosive growth’ of interventional oncology prompts formation of new society

February 10, 2017
The board of directors for World Conference on Interventional Oncology, a nonprofit association that supports and promotes the field, has established…

Eight updates in cancer prevention

February 10, 2017
National Cancer Prevention Month, established by a U.S. Senate resolution and observed every February since 2004, is intended to draw attention to…

In the Journals

Collaboration needed to make molecular imaging a reality for precision oncology

HemOnc Today, February 10, 2017
Molecular imaging can be a “complementary approach” to traditional diagnosis and monitoring methods to help ensure the key goal of…

Commentary

Progress has been slow to realize potential of molecular imaging in precision oncology

HemOnc Today, February 10, 2017
Wafik S. El-Deiry, MD, PhD, FACP
I enjoyed reading the review by Mankoff and colleagues, and I must say that I could not agree more with the authors’ views. However, it is…

More Headlines »
Advertisement
Advertisement